ID   FYN_HUMAN               Reviewed;         537 AA.
AC   P06241; B5BU57; Q16248; Q5R3A6; Q5R3A7; Q8N5D7;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   05-OCT-2010, entry version 148.
DE   RecName: Full=Tyrosine-protein kinase Fyn;
DE            EC=2.7.10.2;
DE   AltName: Full=Proto-oncogene Syn;
DE   AltName: Full=Proto-oncogene c-Fyn;
DE   AltName: Full=Src-like kinase;
DE            Short=SLK;
DE   AltName: Full=p59-Fyn;
GN   Name=FYN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=87089775; PubMed=3099169;
RA   Kawakami T., Pennington C.Y., Robbins K.C.;
RT   "Isolation and oncogenic potential of a novel human src-like gene.";
RL   Mol. Cell. Biol. 6:4195-4201(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   MEDLINE=86287278; PubMed=3526330; DOI=10.1073/pnas.83.15.5459;
RA   Semba K., Nishizawa M., Miyajima N., Yoshida M.C., Sukegawa J.,
RA   Yamanashi Y., Sasaki M., Yamamoto T., Toyoshima K.;
RT   "Yes-related protooncogene, syn, belongs to the protein-tyrosine
RT   kinase family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:5459-5463(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION.
RC   TISSUE=T-cell;
RX   MEDLINE=95123064; PubMed=7822789;
RA   Rigley K., Slocombe P., Proudfoot K., Wahid S., Mandair K.,
RA   Bebbington C.;
RT   "Human p59fyn(T) regulates OKT3-induced calcium influx by a mechanism
RT   distinct from PIP2 hydrolysis in Jurkat T cells.";
RL   J. Immunol. 154:1136-1145(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   MEDLINE=22935763; PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH FYB.
RC   TISSUE=Tonsil;
RX   MEDLINE=97352826; PubMed=9207119; DOI=10.1073/pnas.94.14.7493;
RA   da Silva A.J., Li Z., de Vera C., Canto E., Findell P., Rudd C.E.;
RT   "Cloning of a novel T-cell protein FYB that binds FYN and SH2-domain-
RT   containing leukocyte protein 76 and modulates interleukin 2
RT   production.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:7493-7498(1997).
RN   [9]
RP   MYRISTOYLATION AT GLY-2, AND PHOSPHORYLATION AT TYR-531.
RX   MEDLINE=91016431; PubMed=1699196;
RA   Peters D.J., McGrew B.R., Perron D.C., Liptak L.M., Laudano A.P.;
RT   "In vivo phosphorylation and membrane association of the fyn proto-
RT   oncogene product in IM-9 human lymphoblasts.";
RL   Oncogene 5:1313-1319(1990).
RN   [10]
RP   INTERACTION WITH PIK3R1.
RX   MEDLINE=93348274; PubMed=8394019; DOI=10.1073/pnas.90.15.7366;
RA   Prasad K.V., Janssen O., Kapeller R., Raab M., Cantley L.C.,
RA   Rudd C.E.;
RT   "Src-homology 3 domain of protein kinase p59fyn mediates binding to
RT   phosphatidylinositol 3-kinase in T cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7366-7370(1993).
RN   [11]
RP   TISSUE SPECIFICITY, PHOSPHORYLATION, AND ALTERNATIVE SPLICING.
RX   PubMed=10196263;
RA   Weil R., Levraud J.P., Dodon M.D., Bessia C., Hazan U., Kourilsky P.,
RA   Israel A.;
RT   "Altered expression of tyrosine kinases of the Src and Syk families in
RT   human T-cell leukemia virus type 1-infected T-cell lines.";
RL   J. Virol. 73:3709-3717(1999).
RN   [12]
RP   INTERACTION WITH PAG1.
RX   MEDLINE=20253245; PubMed=10790433; DOI=10.1084/jem.191.9.1591;
RA   Brdicka T., Pavlistova D., Bruyns E., Leo A., Korinek V.,
RA   Angelisova P., Scherer J., Shevchenko A., Shevchenko A., Hilgert I.,
RA   Cerny J., Drbal K., Kuramitsu Y., Horejsi V., Schraven B.;
RT   "Phosphoprotein associated with glycosphingolipid-enriched
RT   microdomains (PAG), a novel ubiquitously expressed transmembrane
RT   adaptor protein, binds the protein tyrosine kinase csk and is involved
RT   in regulation of T cell activation.";
RL   J. Exp. Med. 191:1591-1604(2000).
RN   [13]
RP   INTERACTION WITH HEV ORF3 PROTEIN.
RX   PubMed=11518702; DOI=10.1074/jbc.M101546200;
RA   Korkaya H., Jameel S., Gupta D., Tyagi S., Kumar R., Zafrullah M.,
RA   Mazumdar M., Lal S.K., Xiaofang L., Sehgal D., Das S.R., Sahal D.;
RT   "The ORF3 protein of hepatitis E virus binds to Src homology 3 domains
RT   and activates MAPK.";
RL   J. Biol. Chem. 276:42389-42400(2001).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12218089;
RA   Yasuda K., Nagafuku M., Shima T., Okada M., Yagi T., Yamada T.,
RA   Minaki Y., Kato A., Tani-Ichi S., Hamaoka T., Kosugi A.;
RT   "Fyn is essential for tyrosine phosphorylation of Csk-binding
RT   protein/phosphoprotein associated with glycolipid-enriched
RT   microdomains in lipid rafts in resting T cells.";
RL   J. Immunol. 169:2813-2817(2002).
RN   [15]
RP   FUNCTION.
RX   PubMed=15557120; DOI=10.1083/jcb.200405053;
RA   Meriane M., Tcherkezian J., Webber C.A., Danek E.I., Triki I.,
RA   McFarlane S., Bloch-Gallego E., Lamarche-Vane N.;
RT   "Phosphorylation of DCC by Fyn mediates Netrin-1 signaling in growth
RT   cone guidance.";
RL   J. Cell Biol. 167:687-698(2004).
RN   [16]
RP   INTERACTION WITH ITCH, AND FUNCTION.
RX   PubMed=16387660; DOI=10.1016/j.molcel.2005.11.014;
RA   Yang C., Zhou W., Jeon M.S., Demydenko D., Harada Y., Zhou H.,
RA   Liu Y.C.;
RT   "Negative regulation of the E3 ubiquitin ligase itch via Fyn-mediated
RT   tyrosine phosphorylation.";
RL   Mol. Cell 21:135-141(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-213; TYR-214; TYR-420
RP   AND TYR-440, AND MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [18]
RP   INTERACTION WITH PRMT8.
RX   PubMed=17925405; DOI=10.1074/jbc.M704650200;
RA   Sayegh J., Webb K., Cheng D., Bedford M.T., Clarke S.G.;
RT   "Regulation of protein arginine methyltransferase 8 (PRMT8) activity
RT   by its N-terminal domain.";
RL   J. Biol. Chem. 282:36444-36453(2007).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21 AND TYR-420, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=19007248; DOI=10.1021/ac801708p;
RA   Wang B., Malik R., Nigg E.A., Korner R.;
RT   "Evaluation of the low-specificity protease elastase for large-scale
RT   phosphoproteome analysis.";
RL   Anal. Chem. 80:9526-9533(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21 AND TYR-420, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-25; SER-257 AND
RP   TYR-531, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-15; SER-21; THR-512 AND
RP   TYR-531, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-420, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF SH3 DOMAIN.
RX   MEDLINE=93327750; PubMed=7687536;
RA   Noble M.E.M., Musacchio A., Saraste M., Courtneidge S.A.,
RA   Wierenga R.K.;
RT   "Crystal structure of the SH3 domain in human Fyn; comparison of the
RT   three-dimensional structures of SH3 domains in tyrosine kinases and
RT   spectrin.";
RL   EMBO J. 12:2617-2624(1993).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 81-142.
RX   MEDLINE=95393198; PubMed=7664083; DOI=10.1038/nsb0894-546;
RA   Musacchio A., Saraste M., Wilmanns M.;
RT   "High-resolution crystal structures of tyrosine kinase SH3 domains
RT   complexed with proline-rich peptides.";
RL   Nat. Struct. Biol. 1:546-551(1994).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 85-141 IN COMPLEX WITH NEF.
RX   MEDLINE=96279837; PubMed=8681387; DOI=10.1016/S0092-8674(00)81276-3;
RA   Lee C.H., Saksela K., Mirza U.A., Chait B.T., Kuriyan J.;
RT   "Crystal structure of the conserved core of HIV-1 Nef complexed with a
RT   Src family SH3 domain.";
RL   Cell 85:931-942(1996).
RN   [29]
RP   STRUCTURE BY NMR OF SH3 DOMAIN.
RX   MEDLINE=96399716; PubMed=8805554; DOI=10.1016/S0969-2126(96)00076-7;
RA   Morton C.J., Pugh D.J.R., Brown E.L.J., Kahmann J.D., Renzoni D.A.C.,
RA   Campbell I.D.;
RT   "Solution structure and peptide binding of the SH3 domain from human
RT   Fyn.";
RL   Structure 4:705-714(1996).
RN   [30]
RP   STRUCTURE BY NMR.
RX   MEDLINE=97121261; PubMed=8961927; DOI=10.1021/bi9620969;
RA   Renzoni D.A., Pugh D.J., Siligardi G., Das P., Morton C.J., Rossi C.,
RA   Waterfield M.D., Campbell I.D., Ladbury J.E.;
RT   "Structural and thermodynamic characterization of the interaction of
RT   the SH3 domain from Fyn with the proline-rich binding site on the p85
RT   subunit of PI3-kinase.";
RL   Biochemistry 35:15646-15653(1996).
RN   [31]
RP   STRUCTURE BY NMR OF SH2 DOMAIN.
RX   MEDLINE=98035454; PubMed=9351806; DOI=10.1016/S0969-2126(97)00283-9;
RA   Mulhern T.D., Shaw G.L., Morton C.J., Day A.J., Campbell I.D.;
RT   "The SH2 domain from the tyrosine kinase Fyn in complex with a
RT   phosphotyrosyl peptide reveals insights into domain stability and
RT   binding specificity.";
RL   Structure 5:1313-1323(1997).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 84-144 IN COMPLEX WITH SLAMF1
RP   AND SH2D1A.
RX   PubMed=12545174; DOI=10.1038/ncb920;
RA   Chan B., Lanyi A., Song H.K., Griesbach J., Simarro-Grande M., Poy F.,
RA   Howie D., Sumegi J., Terhorst C., Eck M.J.;
RT   "SAP couples Fyn to SLAM immune receptors.";
RL   Nat. Cell Biol. 5:155-160(2003).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-243; ARG-410 AND GLU-506.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Implicated in the control of cell growth. Plays a role
CC       in the regulation of intracellular calcium levels, with isoform 2
CC       showing the greater ability to mobilize cytoplasmic calcium in
CC       comparison to isoform 1. Required in brain development and mature
CC       brain function with important roles in the regulation of axon
CC       growth, axon guidance, and neurite extension. Blocks axon
CC       outgrowth and attraction induced by NTN1 by phosphorylating its
CC       receptor DDC.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- COFACTOR: Manganese.
CC   -!- ENZYME REGULATION: Inhibited by phosphorylation of Tyr-531 by
CC       leukocyte common antigen and activated by dephosphorylation of
CC       this site.
CC   -!- SUBUNIT: Interacts (via its SH3 domain) with PIK3R1 and PRMT8.
CC       Interacts with FYB, PAG1, and SH2D1A. Interacts with CD79A
CC       (tyrosine-phosphorylated form); the interaction increases FYN
CC       activity (By similarity). Interacts with TOM1L1 (phosphorylated
CC       form) (By similarity). Interacts with SH2D1A and SLAMF1. Interacts
CC       (via its SH3 domain) with HEV ORF3 protein. Interacts with ITCH;
CC       the interaction phosphorylates ITCH and negatively regulates its
CC       activity.
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-515315, EBI-515315;
CC       O92972:- (xeno); NbExp=2; IntAct=EBI-515315, EBI-710506;
CC       P26660:- (xeno); NbExp=1; IntAct=EBI-515315, EBI-706322;
CC       P27958:- (xeno); NbExp=4; IntAct=EBI-515315, EBI-706378;
CC       Q9WMX2:- (xeno); NbExp=2; IntAct=EBI-515315, EBI-710918;
CC       P00519:ABL1; NbExp=1; IntAct=EBI-515315, EBI-375543;
CC       P42684:ABL2; NbExp=1; IntAct=EBI-515315, EBI-1102694;
CC       O43918:AIRE; NbExp=1; IntAct=EBI-515315, EBI-1753081;
CC       Q13023:AKAP6; NbExp=1; IntAct=EBI-515315, EBI-1056102;
CC       Q9BWW9:APOL5; NbExp=1; IntAct=EBI-515315, EBI-1753592;
CC       O15085:ARHGEF11; NbExp=1; IntAct=EBI-515315, EBI-311099;
CC       Q9ULH1:ASAP1; NbExp=1; IntAct=EBI-515315, EBI-346622;
CC       Q9QWY8:Asap1 (xeno); NbExp=2; IntAct=EBI-515315, EBI-698498;
CC       O43150:ASAP2; NbExp=1; IntAct=EBI-515315, EBI-310968;
CC       Q96NS5:ASB16; NbExp=1; IntAct=EBI-515315, EBI-1751918;
CC       Q9UIF9:BAZ2A; NbExp=1; IntAct=EBI-515315, EBI-934890;
CC       P56945:BCAR1; NbExp=1; IntAct=EBI-515315, EBI-702093;
CC       Q63767:Bcar1 (xeno); NbExp=1; IntAct=EBI-515315, EBI-1176801;
CC       P34820:BMP8B; NbExp=1; IntAct=EBI-515315, EBI-1752660;
CC       P51587:BRCA2; NbExp=1; IntAct=EBI-515315, EBI-79792;
CC       Q9ULD4:BRPF3; NbExp=1; IntAct=EBI-515315, EBI-1753470;
CC       P13671:C6; NbExp=1; IntAct=EBI-515315, EBI-1753221;
CC       O60840:CACNA1F; NbExp=1; IntAct=EBI-515315, EBI-1757401;
CC       P20810:CAST; NbExp=1; IntAct=EBI-515315, EBI-1268770;
CC       P32239:CCKBR; NbExp=1; IntAct=EBI-515315, EBI-1753137;
CC       P46092:CCR10; NbExp=1; IntAct=EBI-515315, EBI-348022;
CC       Q9Y5K6:CD2AP; NbExp=1; IntAct=EBI-515315, EBI-298152;
CC       P30260:CDC27; NbExp=1; IntAct=EBI-515315, EBI-994813;
CC       O76039:CDKL5; NbExp=1; IntAct=EBI-515315, EBI-1752465;
CC       Q9NYQ7:CELSR3; NbExp=1; IntAct=EBI-515315, EBI-308417;
CC       P49450:CENPA; NbExp=1; IntAct=EBI-515315, EBI-1751979;
CC       Q13111:CHAF1A; NbExp=1; IntAct=EBI-515315, EBI-1020839;
CC       Q14008:CKAP5; NbExp=1; IntAct=EBI-515315, EBI-310585;
CC       P26992:CNTFR; NbExp=1; IntAct=EBI-515315, EBI-743758;
CC       P78357:CNTNAP1; NbExp=1; IntAct=EBI-515315, EBI-1751903;
CC       Q8WX92:COBRA1; NbExp=1; IntAct=EBI-515315, EBI-347721;
CC       Q7Z408:CSMD2; NbExp=1; IntAct=EBI-515315, EBI-1957312;
CC       P78329:CYP4F2; NbExp=1; IntAct=EBI-515315, EBI-1752413;
CC       P98082:DAB2; NbExp=1; IntAct=EBI-515315, EBI-1171238;
CC       Q14118:DAG1; NbExp=1; IntAct=EBI-515315, EBI-1755945;
CC       Q9UJV9:DDX41; NbExp=1; IntAct=EBI-515315, EBI-1046350;
CC       Q9UK85:DKKL1; NbExp=1; IntAct=EBI-515315, EBI-1753048;
CC       O14490:DLGAP1; NbExp=1; IntAct=EBI-515315, EBI-1753207;
CC       Q9P1A6:DLGAP2; NbExp=1; IntAct=EBI-515315, EBI-1753397;
CC       O95886:DLGAP3; NbExp=1; IntAct=EBI-515315, EBI-1752541;
CC       Q9Y2H0:DLGAP4; NbExp=1; IntAct=EBI-515315, EBI-722139;
CC       Q92988:DLX4; NbExp=1; IntAct=EBI-515315, EBI-1752755;
CC       Q92874:DNASE1L2; NbExp=1; IntAct=EBI-515315, EBI-1751995;
CC       Q9UQ16:DNM3; NbExp=1; IntAct=EBI-515315, EBI-1111783;
CC       Q14185:DOCK1; NbExp=1; IntAct=EBI-515315, EBI-446740;
CC       Q8IZD9:DOCK3; NbExp=1; IntAct=EBI-515315, EBI-1752361;
CC       Q9H1R2:DUSP15; NbExp=1; IntAct=EBI-515315, EBI-1752795;
CC       Q9Y2J2:EPB41L3; NbExp=1; IntAct=EBI-515315, EBI-310986;
CC       P42566:EPS15; NbExp=1; IntAct=EBI-515315, EBI-396684;
CC       O43909:EXTL3; NbExp=1; IntAct=EBI-515315, EBI-1754679;
CC       O00254:F2RL2; NbExp=1; IntAct=EBI-515315, EBI-1751853;
CC       Q9BQ89:FAM110A; NbExp=1; IntAct=EBI-515315, EBI-1752811;
CC       O15360:FANCA; NbExp=1; IntAct=EBI-515315, EBI-81570;
CC       P48023:FASLG; NbExp=1; IntAct=EBI-515315, EBI-495538;
CC       P31994:FCGR2B; NbExp=1; IntAct=EBI-515315, EBI-724784;
CC       P31995:FCGR2C; NbExp=1; IntAct=EBI-515315, EBI-1396036;
CC       P21333:FLNA; NbExp=1; IntAct=EBI-515315, EBI-350432;
CC       Q14315:FLNC; NbExp=1; IntAct=EBI-515315, EBI-489954;
CC       Q12947:FOXF2; NbExp=1; IntAct=EBI-515315, EBI-1752316;
CC       O15117:FYB; NbExp=1; IntAct=EBI-515315, EBI-1753267;
CC       Q9UBS5:GABBR1; NbExp=1; IntAct=EBI-515315, EBI-724156;
CC       Q99259:GAD1; NbExp=1; IntAct=EBI-515315, EBI-743184;
CC       P15586:GNS; NbExp=1; IntAct=EBI-515315, EBI-1752200;
CC       Q9HCN6:GP6; NbExp=1; IntAct=EBI-515315, EBI-515278;
CC       Q9Y5Y3:GPR45; NbExp=1; IntAct=EBI-515315, EBI-1751869;
CC       Q9BZJ6:GPR63; NbExp=1; IntAct=EBI-515315, EBI-1757612;
CC       O43708:GSTZ1; NbExp=1; IntAct=EBI-515315, EBI-748043;
CC       Q92664:GTF3A; NbExp=1; IntAct=EBI-515315, EBI-1752104;
CC       Q02846:GUCY2D; NbExp=1; IntAct=EBI-515315, EBI-1756902;
CC       Q9UL51:HCN2; NbExp=1; IntAct=EBI-515315, EBI-1751885;
CC       Q9Y3Q4:HCN4; NbExp=1; IntAct=EBI-515315, EBI-1753521;
CC       Q9UBN7:HDAC6; NbExp=1; IntAct=EBI-515315, EBI-301697;
CC       P06865:HEXA; NbExp=1; IntAct=EBI-515315, EBI-723519;
CC       O43390:HNRNPR; NbExp=1; IntAct=EBI-515315, EBI-713419;
CC       P31273:HOXC8; NbExp=1; IntAct=EBI-515315, EBI-1752118;
CC       P50406:HTR6; NbExp=7; IntAct=EBI-515315, EBI-1182222;
CC       P26951:IL3RA; NbExp=1; IntAct=EBI-515315, EBI-1757512;
CC       Q9H9L3:ISG20L2; NbExp=1; IntAct=EBI-515315, EBI-751335;
CC       Q07666:KHDRBS1; NbExp=2; IntAct=EBI-515315, EBI-1364;
CC       O43561:LAT; NbExp=1; IntAct=EBI-515315, EBI-1222766;
CC       P50851:LRBA; NbExp=1; IntAct=EBI-515315, EBI-1052167;
CC       Q14767:LTBP2; NbExp=1; IntAct=EBI-515315, EBI-1546118;
CC       Q92918:MAP4K1; NbExp=1; IntAct=EBI-515315, EBI-881;
CC       Q9Y4K4:MAP4K5; NbExp=1; IntAct=EBI-515315, EBI-1279;
CC       O60244:MED14; NbExp=1; IntAct=EBI-515315, EBI-394489;
CC       Q9H204:MED28; NbExp=3; IntAct=EBI-515315, EBI-514199;
CC       Q9NQ76:MEPE; NbExp=1; IntAct=EBI-515315, EBI-1753293;
CC       P46013:MKI67; NbExp=1; IntAct=EBI-515315, EBI-876367;
CC       P00540:MOS; NbExp=1; IntAct=EBI-515315, EBI-1757866;
CC       Q8NFP9:NBEA; NbExp=1; IntAct=EBI-515315, EBI-723014;
CC       O14513:NCKAP5; NbExp=1; IntAct=EBI-515315, EBI-1752508;
CC       Q9NZQ3:NCKIPSD; NbExp=1; IntAct=EBI-515315, EBI-957585;
CC       Q86SG6:NEK8; NbExp=1; IntAct=EBI-515315, EBI-1752987;
CC       O94856:NFASC; NbExp=1; IntAct=EBI-515315, EBI-1751948;
CC       Q9Y697:NFS1; NbExp=1; IntAct=EBI-515315, EBI-1751791;
CC       P43699:NKX2-1; NbExp=1; IntAct=EBI-515315, EBI-1391923;
CC       Q9HCQ7:NPVF; NbExp=1; IntAct=EBI-515315, EBI-1753111;
CC       Q13285:NR5A1; NbExp=1; IntAct=EBI-515315, EBI-874629;
CC       Q13415:ORC1L; NbExp=1; IntAct=EBI-515315, EBI-374847;
CC       P23760:PAX3; NbExp=1; IntAct=EBI-515315, EBI-1167564;
CC       P23759:PAX7; NbExp=1; IntAct=EBI-515315, EBI-1042757;
CC       Q13087:PDIA2; NbExp=1; IntAct=EBI-515315, EBI-1752525;
CC       P98161:PKD1; NbExp=1; IntAct=EBI-515315, EBI-1752013;
CC       P28340:POLD1; NbExp=1; IntAct=EBI-515315, EBI-716569;
CC       O14974:PPP1R12A; NbExp=1; IntAct=EBI-515315, EBI-351726;
CC       O95685:PPP1R3D; NbExp=1; IntAct=EBI-515315, EBI-1045661;
CC       O43900:PRICKLE3; NbExp=1; IntAct=EBI-515315, EBI-1751761;
CC       Q05655:PRKCD; NbExp=3; IntAct=EBI-515315, EBI-704279;
CC       Q04759:PRKCQ; NbExp=6; IntAct=EBI-515315, EBI-374762;
CC       Q9BXM0:PRX; NbExp=1; IntAct=EBI-515315, EBI-1753064;
CC       P29074:PTPN4; NbExp=1; IntAct=EBI-515315, EBI-710431;
CC       Q13905:RAPGEF1; NbExp=1; IntAct=EBI-515315, EBI-976876;
CC       Q86YL6:RICS; NbExp=3; IntAct=EBI-515315, EBI-1210177;
CC       Q86UR5:RIMS1; NbExp=1; IntAct=EBI-515315, EBI-1043236;
CC       Q9UQ26:RIMS2; NbExp=1; IntAct=EBI-515315, EBI-1756749;
CC       Q8TB24:RIN3; NbExp=1; IntAct=EBI-515315, EBI-1570523;
CC       Q8IWN7:RP1L1; NbExp=1; IntAct=EBI-515315, EBI-1757848;
CC       P78345:RPP38; NbExp=1; IntAct=EBI-515315, EBI-366493;
CC       P10301:RRAS; NbExp=1; IntAct=EBI-515315, EBI-968703;
CC       Q9NQC3:RTN4; NbExp=1; IntAct=EBI-515315, EBI-715945;
CC       Q96GP6:SCARF2; NbExp=1; IntAct=EBI-515315, EBI-1752088;
CC       O75326:SEMA7A; NbExp=1; IntAct=EBI-515315, EBI-1753538;
CC       Q9NZV5:SEPN1; NbExp=1; IntAct=EBI-515315, EBI-1751965;
CC       Q15427:SF3B4; NbExp=1; IntAct=EBI-515315, EBI-348469;
CC       Q9BYB0:SHANK3; NbExp=1; IntAct=EBI-515315, EBI-1752330;
CC       Q13796:SHROOM2; NbExp=1; IntAct=EBI-515315, EBI-1644065;
CC       O60721:SLC24A1; NbExp=1; IntAct=EBI-515315, EBI-1753504;
CC       Q9UMY4:SNX12; NbExp=1; IntAct=EBI-515315, EBI-1752602;
CC       Q15036:SNX17; NbExp=1; IntAct=EBI-515315, EBI-1752620;
CC       O14559:SNX26; NbExp=1; IntAct=EBI-515315, EBI-1210010;
CC       O60493:SNX3; NbExp=1; IntAct=EBI-515315, EBI-727209;
CC       Q9Y5X2:SNX8; NbExp=1; IntAct=EBI-515315, EBI-1752557;
CC       Q07889:SOS1; NbExp=1; IntAct=EBI-515315, EBI-297487;
CC       Q07890:SOS2; NbExp=1; IntAct=EBI-515315, EBI-298181;
CC       P08047:SP1; NbExp=1; IntAct=EBI-515315, EBI-298336;
CC       Q9NYA1:SPHK1; NbExp=1; IntAct=EBI-515315, EBI-985303;
CC       Q8CI15:Sphk1 (xeno); NbExp=1; IntAct=EBI-515315, EBI-985291;
CC       Q9NRA0:SPHK2; NbExp=1; IntAct=EBI-515315, EBI-985324;
CC       Q9JIA7:Sphk2 (xeno); NbExp=1; IntAct=EBI-515315, EBI-985434;
CC       Q9H5I1:SUV39H2; NbExp=1; IntAct=EBI-515315, EBI-723127;
CC       O15056:SYNJ2; NbExp=1; IntAct=EBI-515315, EBI-310513;
CC       P16383:TCF9; NbExp=1; IntAct=EBI-515315, EBI-954074;
CC       Q9BXT4:TDRD1; NbExp=1; IntAct=EBI-515315, EBI-1757688;
CC       O43493:TGOLN2; NbExp=1; IntAct=EBI-515315, EBI-1752146;
CC       P42167:TMPO; NbExp=1; IntAct=EBI-515315, EBI-455283;
CC       Q9BWF2:TRAIP; NbExp=1; IntAct=EBI-515315, EBI-1756205;
CC       Q9HCM9:TRIM39; NbExp=1; IntAct=EBI-515315, EBI-739510;
CC       Q9UJT2:TSKS; NbExp=1; IntAct=EBI-515315, EBI-852101;
CC       O00294:TULP1; NbExp=1; IntAct=EBI-515315, EBI-1756778;
CC       Q9NRJ4:TULP4; NbExp=1; IntAct=EBI-515315, EBI-1753487;
CC       Q96RL7:VPS13A; NbExp=1; IntAct=EBI-515315, EBI-1752583;
CC       Q9UMN6:WBP7; NbExp=1; IntAct=EBI-515315, EBI-765774;
CC       O43516:WIPF1; NbExp=1; IntAct=EBI-515315, EBI-346356;
CC       Q9Y3S1:WNK2; NbExp=1; IntAct=EBI-515315, EBI-948521;
CC       P18887:XRCC1; NbExp=1; IntAct=EBI-515315, EBI-947466;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Note=Present and active in
CC       lipid rafts. Present in cell body and along the process of mature
CC       and developing oligodendroyctes.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=B;
CC         IsoId=P06241-1; Sequence=Displayed;
CC       Name=2; Synonyms=T;
CC         IsoId=P06241-2; Sequence=VSP_024109, VSP_024110;
CC       Name=3;
CC         IsoId=P06241-3; Sequence=VSP_024108;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is highly expressed in the brain.
CC       Isoform 2 is expressed in cells of hemopoietic lineages,
CC       especially T lymphocytes.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- SIMILARITY: Contains 1 SH3 domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14676; AAA36615.1; -; mRNA.
DR   EMBL; M14333; AAC08285.1; -; mRNA.
DR   EMBL; S74774; AAB33113.2; -; mRNA.
DR   EMBL; AB451293; BAG70107.1; -; mRNA.
DR   EMBL; AB451426; BAG70240.1; -; mRNA.
DR   EMBL; Z97989; CAI22300.1; -; Genomic_DNA.
DR   EMBL; Z97989; CAI22301.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48278.1; -; Genomic_DNA.
DR   EMBL; BC032496; AAH32496.1; -; mRNA.
DR   IPI; IPI00166845; -.
DR   IPI; IPI00219012; -.
DR   IPI; IPI00640091; -.
DR   PIR; A24314; TVHUSY.
DR   RefSeq; NP_002028.1; -.
DR   RefSeq; NP_694592.1; -.
DR   RefSeq; NP_694593.1; -.
DR   UniGene; Hs.390567; -.
DR   PDB; 1A0N; NMR; -; B=82-148.
DR   PDB; 1AOT; NMR; -; F=143-248.
DR   PDB; 1AOU; NMR; -; F=143-248.
DR   PDB; 1AVZ; X-ray; 3.00 A; C=85-140.
DR   PDB; 1AZG; NMR; -; B=82-148.
DR   PDB; 1EFN; X-ray; 2.50 A; A/C=86-143.
DR   PDB; 1FYN; X-ray; 2.30 A; A=81-142.
DR   PDB; 1G83; X-ray; 2.60 A; A/B=82-245.
DR   PDB; 1M27; X-ray; 2.50 A; C=84-144.
DR   PDB; 1NYF; NMR; -; A=82-148.
DR   PDB; 1NYG; NMR; -; A=82-148.
DR   PDB; 1SHF; X-ray; 1.90 A; A/B=84-142.
DR   PDB; 1ZBJ; NMR; -; A=84-141.
DR   PDB; 2DQ7; X-ray; 2.80 A; X=261-536.
DR   PDB; 3H0F; X-ray; 2.61 A; A=73-142.
DR   PDB; 3H0H; X-ray; 1.76 A; A=73-142.
DR   PDB; 3H0I; X-ray; 2.20 A; A/B=73-142.
DR   PDBsum; 1A0N; -.
DR   PDBsum; 1AOT; -.
DR   PDBsum; 1AOU; -.
DR   PDBsum; 1AVZ; -.
DR   PDBsum; 1AZG; -.
DR   PDBsum; 1EFN; -.
DR   PDBsum; 1FYN; -.
DR   PDBsum; 1G83; -.
DR   PDBsum; 1M27; -.
DR   PDBsum; 1NYF; -.
DR   PDBsum; 1NYG; -.
DR   PDBsum; 1SHF; -.
DR   PDBsum; 1ZBJ; -.
DR   PDBsum; 2DQ7; -.
DR   PDBsum; 3H0F; -.
DR   PDBsum; 3H0H; -.
DR   PDBsum; 3H0I; -.
DR   ProteinModelPortal; P06241; -.
DR   SMR; P06241; 84-537.
DR   IntAct; P06241; 209.
DR   MINT; MINT-93594; -.
DR   STRING; P06241; -.
DR   PhosphoSite; P06241; -.
DR   PRIDE; P06241; -.
DR   Ensembl; ENST00000368667; ENSP00000357656; ENSG00000010810.
DR   Ensembl; ENST00000368678; ENSP00000357667; ENSG00000010810.
DR   GeneID; 2534; -.
DR   KEGG; hsa:2534; -.
DR   UCSC; uc003pvh.1; human.
DR   UCSC; uc003pvi.1; human.
DR   UCSC; uc003pvj.1; human.
DR   CTD; 2534; -.
DR   GeneCards; GC06M111981; -.
DR   H-InvDB; HIX0006144; -.
DR   HGNC; HGNC:4037; FYN.
DR   HPA; CAB005034; -.
DR   HPA; CAB018387; -.
DR   HPA; HPA023887; -.
DR   MIM; 137025; gene.
DR   PharmGKB; PA28454; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P06241; -.
DR   OMA; TQSSGYR; -.
DR   OrthoDB; EOG9PP12J; -.
DR   PhylomeDB; P06241; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Pathway_Interaction_DB; alphasynuclein_pathway; Alpha-synuclein signaling.
DR   Pathway_Interaction_DB; amb2_neutrophils_pathway; amb2 Integrin signaling.
DR   Pathway_Interaction_DB; angiopoietinreceptor_pathway; Angiopoietin receptor Tie2-mediated signaling.
DR   Pathway_Interaction_DB; pi3kcipathway; Class I PI3K signaling events.
DR   Pathway_Interaction_DB; epha_fwdpathway; EPHA forward signaling.
DR   Pathway_Interaction_DB; ephrinarevpathway; Ephrin A reverse signaling.
DR   Pathway_Interaction_DB; ephrinbrevpathway; Ephrin B reverse signaling.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   Pathway_Interaction_DB; glypican_1pathway; Glypican 1 network.
DR   Pathway_Interaction_DB; il2_1pathway; IL2-mediated signaling events.
DR   Pathway_Interaction_DB; pdgfrbpathway; PDGFR-beta signaling pathway.
DR   Pathway_Interaction_DB; reelinpathway; Reelin signaling pathway.
DR   Pathway_Interaction_DB; p38alphabetapathway; Regulation of p38-alpha and p38-beta.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   Pathway_Interaction_DB; syndecan_3_pathway; Syndecan-3-mediated signaling events.
DR   Pathway_Interaction_DB; tcrpathway; TCR signaling in naive CD4+ T cells.
DR   Pathway_Interaction_DB; cd8tcrpathway; TCR signaling in naive CD8+ T cells.
DR   Pathway_Interaction_DB; txa2pathway; Thromboxane A2 receptor signaling.
DR   Reactome; REACT_18266; Axon guidance.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6185; HIV Infection.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   DrugBank; DB01254; Dasatinib.
DR   NextBio; 9997; -.
DR   PMAP-CutDB; P06241; -.
DR   ArrayExpress; P06241; -.
DR   Bgee; P06241; -.
DR   CleanEx; HS_FYN; -.
DR   Genevestigator; P06241; -.
DR   GermOnline; ENSG00000010810; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005768; C:endosome; IDA:HGNC.
DR   GO; GO:0005886; C:plasma membrane; IDA:HGNC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0001948; F:glycoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; NAS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; NAS:UniProtKB.
DR   GO; GO:0007631; P:feeding behavior; TAS:ProtInc.
DR   GO; GO:0044419; P:interspecies interaction between organisms; IEA:UniProtKB-KW.
DR   GO; GO:0007243; P:intracellular protein kinase cascade; TAS:ProtInc.
DR   GO; GO:0007612; P:learning; TAS:ProtInc.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR020745; Tyr_kinase_non-rcpt_Fyn.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:3.30.505.10; SH2; 1.
DR   PANTHER; PTHR23256:SF256; Tyr_kinase_non-rcpt_Fyn; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF50044; SH3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Developmental protein; Host-virus interaction;
KW   Kinase; Lipoprotein; Manganese; Membrane; Metal-binding; Myristate;
KW   Nucleotide-binding; Palmitate; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; SH2 domain; SH3 domain; Transferase;
KW   Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    537       Tyrosine-protein kinase Fyn.
FT                                /FTId=PRO_0000088099.
FT   DOMAIN       82    143       SH3.
FT   DOMAIN      149    246       SH2.
FT   DOMAIN      271    524       Protein kinase.
FT   NP_BIND     277    285       ATP (By similarity).
FT   ACT_SITE    390    390       Proton acceptor (By similarity).
FT   BINDING     299    299       ATP (By similarity).
FT   MOD_RES      12     12       Phosphothreonine; by PKC (By similarity).
FT   MOD_RES      15     15       Phosphothreonine.
FT   MOD_RES      21     21       Phosphoserine.
FT   MOD_RES      25     25       Phosphoserine.
FT   MOD_RES     185    185       Phosphotyrosine (By similarity).
FT   MOD_RES     213    213       Phosphotyrosine.
FT   MOD_RES     214    214       Phosphotyrosine.
FT   MOD_RES     254    254       Phosphothreonine (By similarity).
FT   MOD_RES     257    257       Phosphoserine.
FT   MOD_RES     420    420       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     440    440       Phosphotyrosine.
FT   MOD_RES     512    512       Phosphothreonine.
FT   MOD_RES     531    531       Phosphotyrosine.
FT   LIPID         2      2       N-myristoyl glycine.
FT   LIPID         3      3       S-palmitoyl cysteine (By similarity).
FT   LIPID         6      6       S-palmitoyl cysteine (By similarity).
FT   VAR_SEQ     233    287       Missing (in isoform 3).
FT                                /FTId=VSP_024108.
FT   VAR_SEQ     234    236       RAA -> KAD (in isoform 2).
FT                                /FTId=VSP_024109.
FT   VAR_SEQ     240    283       CRLVVPCHKGMPRLTDLSVKTKDVWEIPRESLQLIKRLGNG
FT                                QFG -> FNLTVIASSCTPQTSGLAKDAWEVARRSLCLEKK
FT                                LGQGCFA (in isoform 2).
FT                                /FTId=VSP_024110.
FT   VARIANT     243    243       V -> L (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041704.
FT   VARIANT     410    410       G -> R (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041705.
FT   VARIANT     445    445       I -> F (in dbSNP:rs1801121).
FT                                /FTId=VAR_014661.
FT   VARIANT     506    506       D -> E (in dbSNP:rs28763975).
FT                                /FTId=VAR_041706.
FT   CONFLICT    184    184       A -> S (in Ref. 1; AAA36615).
FT   CONFLICT    287    287       M -> L (in Ref. 3; AAB33113 and 4;
FT                                CAI22301).
FT   CONFLICT    437    437       A -> R (in Ref. 1; AAA36615 and 3;
FT                                AAB33113).
FT   STRAND       86     91
FT   STRAND       97    100
FT   STRAND      108    113
FT   STRAND      117    124
FT   TURN        125    127
FT   STRAND      130    134
FT   HELIX       135    137
FT   STRAND      138    140
FT   HELIX       144    146
FT   STRAND      147    150
FT   HELIX       156    164
FT   STRAND      173    177
FT   STRAND      179    181
FT   STRAND      185    192
FT   STRAND      194    196
FT   STRAND      198    207
FT   STRAND      220    223
FT   HELIX       224    233
FT   STRAND      238    240
FT   STRAND      263    265
FT   HELIX       268    270
FT   STRAND      271    278
FT   STRAND      285    290
FT   TURN        291    293
FT   STRAND      294    299
FT   TURN        303    305
FT   HELIX       308    318
FT   STRAND      329    333
FT   STRAND      335    337
FT   STRAND      339    343
FT   HELIX       350    354
FT   STRAND      355    357
FT   TURN        358    360
FT   HELIX       364    383
FT   HELIX       393    395
FT   STRAND      396    399
FT   TURN        400    402
FT   STRAND      403    406
FT   STRAND      416    418
FT   TURN        430    432
FT   HELIX       435    438
FT   HELIX       445    460
FT   HELIX       472    481
FT   HELIX       496    502
FT   HELIX       507    509
FT   HELIX       513    521
SQ   SEQUENCE   537 AA;  60762 MW;  4A1E443A4B5A0977 CRC64;
     MGCVQCKDKE ATKLTEERDG SLNQSSGYRY GTDPTPQHYP SFGVTSIPNY NNFHAAGGQG
     LTVFGGVNSS SHTGTLRTRG GTGVTLFVAL YDYEARTEDD LSFHKGEKFQ ILNSSEGDWW
     EARSLTTGET GYIPSNYVAP VDSIQAEEWY FGKLGRKDAE RQLLSFGNPR GTFLIRESET
     TKGAYSLSIR DWDDMKGDHV KHYKIRKLDN GGYYITTRAQ FETLQQLVQH YSERAAGLCC
     RLVVPCHKGM PRLTDLSVKT KDVWEIPRES LQLIKRLGNG QFGEVWMGTW NGNTKVAIKT
     LKPGTMSPES FLEEAQIMKK LKHDKLVQLY AVVSEEPIYI VTEYMNKGSL LDFLKDGEGR
     ALKLPNLVDM AAQVAAGMAY IERMNYIHRD LRSANILVGN GLICKIADFG LARLIEDNEY
     TARQGAKFPI KWTAPEAALY GRFTIKSDVW SFGILLTELV TKGRVPYPGM NNREVLEQVE
     RGYRMPCPQD CPISLHELMI HCWKKDPEER PTFEYLQSFL EDYFTATEPQ YQPGENL
//
